Effects of a reduction-to-quit smoking programme in patients with COPD: the REDUQ study.
Recruiting
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPDLung emphysema and chronic bronchitisSmokingTobacco addictionNicotine dependence Smoking cessation Smoking reduction
- Registration Number
- NL-OMON24119
- Lead Sponsor
- niversity of Twente, Dept. Psychology & Communication of Health & Risk; Depts Pulmonolgy of University Medical Center Groningen, Slotervaart Hospital, Catharina Hospital and Medisch Spectrum Twente
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 262
Inclusion Criteria
1. COPD, GOLD stage I-IV;
2. Age 40-80 years;
Exclusion Criteria
1. Motivated to quit smoking within 1 month from baseline (= ready to quit);
2. Not able to speak, read and write Dutch;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome parameter is the percentage of patients with continuous cotinine-validated abstinence after two years from baseline, for at least the last full year.<br><br /><br /><br>Continuous abstinence is defined as having salivary cotinine levels < 20ng/mL at measurements at 12 and 24 months.<br>
- Secondary Outcome Measures
Name Time Method 1. Smoking reduction / decrease of the daily cigarette consumption;<br /><br>2. Behavioural prognostic determinants of smoking reduction and cessation (e.g. attitude, self-efficacy, nicotine dependence);<br /><br>3. Point prevalence abstinence rates at 12, 18, and 24 months;<br /><br>4. Disease-specific QoL;<br /><br>5. Lung function (FEV1, IVC, FEV1/IVC, FEV1% predicted);<br /><br>6. Frequency and severity of exacerbations;<br /><br>7. Disease-specific symptoms (breathlessness, coughing, sputum production);<br /><br>8. Motivation/readiness to quit smoking;<br /><br>9. Cost-effectiveness data.